Ann: Canaccord US Growth Conference Presentation, page-28

uhm..again, the info about manufacturing increase is detailed in all the AT1 info on their website, in this forum etc
- their South African site is expected to double (500k devices/month) this month (Aug2020)
- then they will double this again by Jan2021 (1.3m devices/month)
- the CEO has also mentioned options for USA based manufacturing option (in 2021). In another past investor presentation, he also mentioned possibility of other 'offshore manufacturing' (meaning non-South African based site) but won't focus on this till 2021

Their global partners Access Bio/NgBioTech also have their manufacturing sites for other test devices/products. Its not clear yet, but no doubt if these partnerships are successful, some sort of licensing arrangement could un-fold....nothing mentioned about this yet, to be clear.

Nothing about AT1 suggests they are looking to just scale up will-nilly with any partner anywhere just to produce millions of devices by next Sunday just for Covid. They supply devices for HIV, malaria etc as OEM. These are serology medical test devices and heavily regulated with exacting manufacturing standards, sterility requirements etc (and come with enormous expectations to perform exactly as expected).

The CEO has always talked about not just selecting partner agreements with an eye on short term profits. They want to build a global biz.and everything is geared towards tripling supply of AT1 devices (within first year of listing), whilst still keeping long term view beyond Covid19 only focus.